BRPA News and Press, NRX Pharmaceuticals Inc Com From 04/07/21

Gainers: Cohen & Company (COHN) +25%. Pintec Technology Holdings (PT) +17%. Altimeter Growth (AGCUU) +9%. Altimeter Growth (AGC) +8%. U.S. Global Investors (GROW) +7%.Losers: The GEO Group (GEO) -20%. Big Rock Partners Acquisition (BRPA) -12%. Hywin Holdings (HYW) -12%. Upstart Holdings (...

NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir PR Newswire RADNOR, Pa. , April 6, 2021 /PRNewswire/ -- NeuroRx, Inc. reports today that Aviptadil, to be...

Gainers: X Financial (XYF) +15%. Marathon Digital Holdings (MARA) +11%. 360 DigiTech (QFIN) +10%. FinVolution Group (FINV) +10%. ARYA Sciences Acquisition (ARYA) +9%.Losers: Big Rock Partners Acquisition (BRPA) -10%. Stable Road Acquisition (SRAC) -9%. Holicity (HOL) -9%. Atlantic American (A...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning and welcome to the stock market today! The Ever Given is free , Wall Street is caught up in a fire sale tizzy and cryptos are climbing again. So what will the stock market do today? And what do you need to kno...

Universe Pharmaceuticals (UPC) +113%.Humanigen (HGEN) +61% on positive Phase 3 data for COVID-19 therapy.Cyanotech Corporation (CYAN) +48%.Big Rock Partners Acquisition (BRPA) +42%.SeaChange International (SEAC) +34% on multi-million-dollar contract with broadband service provider.F...

/C O R R E C T I O N -- NeuroRx/ PR Newswire In the news release, NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b /3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19, issued ...

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 PR Newswire RADNOR, Pa. , March 29, 2021 /PRNewswire/ -- NeuroRx, I...

NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure Results to be Presented at Investor Call on Monday, March 29th at 8:30am EDT PR Newswire RADNOR, Pa. , March 26, 2021...

WILMINGTON, DE and DELRAY BEACH, FL / ACCESSWIRE / March 15, 2021 / NeuroRx, Inc. ("NeuroRx"), a clinical stage-small molecule pharmaceutical company and Big Rock Partners Acquisition Corp. ("Big Rock") (NASDAQ:BRPA), a special purpose acquisition company, are pleased to announce that inst...

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration Feasibility work underway to determine the compatibility of NeuroRx's ZYESAMI™ (aviptadil, synthetic VIP) as a dry powder formulation using TFF's Thin-Film Freezing technology Dry powder ...